Catherine Marsteller, MD
Internal Medicine · Richmond, INNPI 1629286141
Payments from drug & device makers
Across 80 payments — averaging $13.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$266
- Novo Nordisk$186
- AstraZeneca$115
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$78
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$58
- Axsome Therapeutics, Inc.$58
- plus $333 from 12 others
What the payments were for
- Food & beverage$1,093100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $266 |
| Novo Nordisk | 15 | $186 |
| AstraZeneca | 5 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $78 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $58 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Astellas Pharma US Inc | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $53 |
| Lilly USA, LLC | 3 | $44 |
| Gilead | 2 | $31 |
| Abbott | 2 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Biogen | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$1,093 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $193,269 |
| AustedoDeutetrabenazine | 13 | $83,503 |
| Humira PenAdalimumab | 11 | $74,704 |
| RybelsusSemaglutide | 34 | $56,472 |
| TrulicityDulaglutide | 38 | $52,495 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $51,820 |
| JanuviaSitagliptin Phosphate | 48 | $47,685 |
| MounjaroTirzepatide | 33 | $44,424 |
| EliquisApixaban | 48 | $37,016 |
| LinzessLinaclotide | 41 | $27,975 |
| JardianceEmpagliflozin | 21 | $20,005 |
| MovantikNaloxegol Oxalate | 44 | $19,799 |
| MyrbetriqMirabegron | 36 | $17,851 |
| VraylarCariprazine Hcl | 12 | $16,872 |
| Advair HfaFluticasone Propion/Salmeterol | 32 | $15,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $186 | $249,741212 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $44 | $96,91971 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $14 | $83,50313 claims |
| AbbVieLinzess, Vraylar | $266 | $44,84753 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $17,85136 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $53 | $12,58622 claims |
| AstraZenecaBreztri Aerosphere | $115 | $10,42316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Richmond
- Alex GilmanRichmond$23K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.